{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-005540","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.798987+00:00","generated_at":"2026-06-11T14:00:16.086593+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sunshine Biopharma Q2 2023 revenues jump 3,600% YoY to $5.56M","bullets":["Revenues of $5,560,865 for Q2 2023, a 3,600% increase over Q2 2022.","Revenue growth driven by Nora Pharma generic drug sales, acquired Oct 2022.","Q2 2023 revenues up 13.6% sequentially from Q1 2023.","CEO Dr. Steve Slilaty expressed optimism for continued growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-005540","json":"https://secwatch.observer/filing/0001683168-23-005540.json","markdown":"https://secwatch.observer/filing/0001683168-23-005540.md","text":"https://secwatch.observer/filing/0001683168-23-005540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823005540/0001683168-23-005540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823005540/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:00:16.086593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b64f74a08ba5f619ca6ab304e0b6f7b49314a4d","claim":"Sunshine Biopharma Inc. reported the 2023 second quarter results: revenue $5,560,865.","evidence_excerpt":"of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 second quarter. The Company reported gross revenues of $5,560,865 for the quarter ended June 30, 2023, an increase of 3,600% over the same period in 2022. The increase was largely due to the prescription drugs sales of Nora Pharma Inc., a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316823005540/0001683168-23-005540-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the 2023 second quarter"},{"label":"Revenue","value":"$5,560,865"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}